Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]: Side Effects & Safety Data for 5 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] includes 5 drugs with a combined 24,004 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
5
Drugs in Class
24,004
Combined Reports
All Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| EFAVIRENZ | Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate | 7,893 | 962 | 1,528 | 12.2% |
| RILPIVIRINE | EDURANT | 7,049 | 196 | 593 | 2.8% |
| NEVIRAPINE | Nevirapine | 6,651 | 1,101 | 979 | 16.6% |
| ETRAVIRINE | Intelence | 1,969 | 257 | 405 | 13.1% |
| DORAVIRINE | PIFELTRO | 442 | 50 | 94 | 11.3% |
Common Side Effects in Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Virologic failure | 2,349 | 74 |
| Foetal exposure during pregnancy | 2,278 | 412 |
| Drug resistance | 1,896 | 148 |
| Viral mutation identified | 1,534 | 7 |
| Pathogen resistance | 1,398 | 13 |
| Treatment failure | 1,091 | 170 |
| Death | 1,084 | 1,081 |
| Exposure during pregnancy | 991 | 59 |
| Maternal exposure during pregnancy | 867 | 67 |
| Drug interaction | 841 | 165 |